Le Lézard
Classified in: Health, Business
Subject: ECO

BDC Capital Inc. sells Common shares of Clementia Pharmaceuticals Inc.


MONTRÉAL, Jan. 11, 2019 /CNW Telbec/ - On January 11, 2019, BDC Capital Inc. ("BDC Capital"), a wholly-owned subsidiary of the Business Development Bank of Canada (the "BDC"), sold 396 common shares (the "Common Shares") in the capital of Clementia Pharmaceuticals Inc. ("Clementia") on the NASDAQ Stock Market (the "Sale") at an average price of US$14.0976 per Common Share (C$18.6920 per Common Share based on the Bank of Canada exchange rate on January 11, 2019), for aggregate gross proceeds to BDC Capital of US$5,582.65 (C$7,402.04 based on the Bank of Canada exchange rate on January 11, 2019).  

Immediately prior to the Sale, BDC beneficially owned or had control or direction over, directly or indirectly, an aggregate of 5,497,607 Common Shares, representing approximately 14.539% of the issued and outstanding Common Shares. As of January 11, 2019, after giving effect to the Sale, BDC beneficially owns or has control or direction over, directly or indirectly, an aggregate of 5,497,211 Common Shares, representing approximately 14.538% of the issued and outstanding Common Shares.

BDC Capital sold the Common Shares as a result of an investment decision and, based on current market conditions, BDC Capital currently intends to dispose of additional Common Shares. BDC Capital may in the future wish to increase or further decrease its shareholdings in Clementia as circumstances warrant, whether in the open market, by privately negotiated agreements, or otherwise. Any transaction that BDC Capital may pursue may be made at any time and from time to time without prior notice and will depend on a variety of factors, including, without limitation, the price and availability of common shares of Clementia, subsequent developments affecting Clementia, its business and prospects, other investment and business opportunities available to BDC Capital, general industry and economic conditions, the securities markets in general, compliance with applicable securities laws and other factors deemed relevant by BDC Capital.

An early warning report relating to this transaction will be filed on SEDAR under Clementia's profile at www.sedar.com. To obtain a copy of such report, please contact Joanne Lajeunesse, Marketing and Public Affairs, at 514-461-2739. The head office of BDC Capital is located at 5 Place Ville-Marie, Suite 300, Montréal, Québec, H3B 5E7. The BDC is Canada's business development bank, a financial institution dedicated exclusively to entrepreneurs. The head office of Clementia is located at 550-4150 Sainte-Catherine West, Montréal, Québec, H3Z 2Y5.

 

SOURCE BDC Capital


These press releases may also interest you

16 jan 2019
Mirati Therapeutics, Inc. today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are expected to be...

16 jan 2019
PharmaCielo Ltd. (the "Company" or "PharmaCielo"), formerly AAJ Capital 1 Corp. ("AAJ") is pleased to announce that effective January 15, 2019, it completed its previously announced qualifying transaction (the "Qualifying Transaction") pursuant to...

16 jan 2019
ENCINO, Calif., Jan. 16, 2019 /PRNewswire-PRWeb/ -- Parents and children alike are learning skills for anxiety relief, and other tools for mental wellness, from a new podcast. Dear Anxiety, a production of GoZen!, premiered in January 2019 and made...

16 jan 2019
This report analyzes the worldwide markets for Prepackaged Medical Kits and Trays in US$ Thousand by the following Product Segments: ENT Custom Trays, Ophthalmic Custom Trays, Custom Basin Kits, Custom Ob/Gyn Kits, General Delivery Kits, Hysterectomy...

16 jan 2019
KEY FINDINGSThe global small cell market is forecasted to rise at a CAGR of 25.16% for the period 2019-2027, generating $XX million revenue at the end of 2027. The market is mainly driven by factors such as the growing propagation of small cells,...

16 jan 2019
This report analyzes the worldwide markets for Intraocular Lenses in US$ Thousand and Thousand Units by the following Segments: Standard Intraocular Lenses, and Premium Intraocular Lenses.Read the full report: https://www.reportlinker.com/p05205331...



News published on 11 january 2019 at 20:26 and distributed by: